Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 67Stomach Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Inflammatory Breast Neoplasms 3Breast Neoplasms, Male 3Solid Tumor 2Rectal Neoplasms 2Prostatic Neoplasms 2HER2-positive Breast Cancer 2Colonic Neoplasms 2Carcinoma, Ductal, Breast 2Urinary Bladder Neoplasms 1Solid Cancers 1Patient Preference 1Neoplasms, Unknown Primary 1Metastatic HER2-Positive Breast Cancer 1Lung Neoplasms 1Her2-Positive Breast Cancer 1HER2-positive Early Breast Cancer 1HER2-Positive Early Breast Cancer 1HER2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Elderly Metastatic Breast Cancer Population 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Biliary Tract Neoplasms 1

Interventions

Carboplatin 87Paclitaxel 77Bevacizumab 38Topotecan 23liposomal doxorubicin 22Gemcitabine 22Taxes 21Cisplatin 17Drug Therapy 14Docetaxel 14Cyclophosphamide 14pembrolizumab 13Immunoglobulin G 12Disulfides 12veliparib 8rucaparib 8mirvetuximab soravtansine 8niraparib 7Albumin-Bound Paclitaxel 7sargramostim 6Filgrastim 6Erlotinib Hydrochloride 6Doxorubicin 6pazopanib 5Granulocyte-Macrophage Colony-Stimulating Factor 5Chemotherapy, Adjuvant 5CP protocol 5trebananib 4temsirolimus 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fallopian Tube Neoplasms × pertuzumab × Clear all
NCT00096993 2015-06-10

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Genentech, Inc.

Phase 2 Completed
131 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡